NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis

Praxis Precision Medicines, Inc. (PRAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PRAX

$351.81

−$3.34 (−0.94%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRAX with… →

PRAX Key Statistics

As of Sep 4, 2026
Trading
Open
$352.99
Previous Close
$355.15
Day's Range
349.82–357.50
52-Week Range
37.19–392.70
Volume
175.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.78
Valuation
Market Cap
$9.82B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.83
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$303.27M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.92M
1-Year Return
+663.31%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
464.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRAX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+19.36%
2025+282.98%
2024+245.42%
2023−37.59%
2022−87.92%
2021−64.19%
2020 (partial year)+97.91%

As of September 4, 2026.

PRAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$303.27M—
2024$8.55M−$182.82M−2137.5%
2023$2.45M−$123.28M−5037.9%
2022$0.00−$214.03M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$326.20M−$303.27M—
2024$8.55M—−$200.17M−$182.82M−2137.5%
2023$2.45M—−$126.37M−$123.28M−5037.9%
2022$0.00—−$214.99M−$214.03M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRAX Valuation vs Biotechnology Median

Median of 656 stocks
MetricPRAXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Praxis Precision Medicines, Inc. (PRAX) carries a market capitalisation of $9.82B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 168.

The most recent close on file for PRAX is $351.81, dated September 4, 2026. That is −$3.34 (−0.94%) against the previous close. Over the past 52 weeks the price has ranged from $37.19 to $392.70. The latest close sits 845.98% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. That is −100.00% against the prior fiscal year, when revenue was $8.55M. The same year closed with a net loss of $303.27M. Profit margin runs at 0%. Trailing earnings per share are −12.83.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +663.31%. Across 5 years the annualized return works out at +1.81%. The reported beta is 2.78. Daily returns over the trailing 5 years annualize to a volatility of 127.26%.

Growth & Income

The record shows no dividend for PRAX.

2026 is still running; the price is +19.36% year to date. Across the complete calendar years on file, 2025 returned +282.98% and 2022 returned −87.92%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Praxis Precision Medicines, Inc. (PRAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Praxis Precision Medicines, Inc. PRAX $9.82B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Praxis Precision Medicines, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Visit website →